20:58 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Alexo reports preliminary Phase I data for ALX148 in solid tumors and lymphoma

In November, Alexo Therapeutics Ltd. (Dublin, Ireland) reported preliminary data from 17 patients with advanced solid tumors and lymphoma in a Phase I trial showing that IV ALX148 was well tolerated with 1 treatment-related serious...
19:35 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; melanoma Cell culture and mouse studies suggest inhibiting MHCI, MHCI components or the macrophage MHC1 binding partner LILRB1 could help treat pancreatic cancer and melanoma. In co-culture of human pancreatic neuroendocrine...
22:06 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Alexo reports Phase I data for its CD47 inhibitor

Alexo Therapeutics Ltd. (Dublin, Ireland) reported data from 17 patients with advanced solid tumors and lymphoma in the single-agent portion of an open-label, dose-escalation Phase I trial showing that 0.3-30 mg/kg doses of ALX148 monotherapy...
16:30 , Apr 14, 2017 |  BC Week In Review  |  Clinical News

ALX148: Ph I AT148001 started

Alexo began the 2-part, open-label, dose-escalation, U.S. Phase I AT148001 trial to evaluate ALX148 in about 110 patients. Part 1 will evaluate ascending doses of ALX148 given alone weekly or every 2 weeks. Part 2...
07:00 , Aug 25, 2016 |  BC Innovations  |  Targets & Mechanisms

Forty Seven and counting

With companies lining up to block CD47 for cancer, the cell surface protein is emerging as one of the top new targets in oncology. But the list of suitors could be about to get a...
07:00 , Jul 25, 2016 |  BioCentury  |  Emerging Company Profile

Targeted phagocytosis

Alexo Therapeutics Inc. is developing variants of signal regulatory protein alpha that antagonize CD47 to increase macrophage phagocytosis induced by anticancer antibodies. Using the variants alongside antibody therapeutics could avoid on-target phagocytosis of healthy cells...